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Abstract
Abstract 1: α-Amylase is an important enzyme in the body responsible for hydrolyzing many
polysaccharides such as dietary starch. Inhibition of this enzyme could be extremely beneficial in diabetic
patients because it could lower the glucose levels in the blood. Our objective is to synthesize a small
analog of a natural α-amylase inhibitor, Tendamistat. This molecule has 15-22 residue segment that are
critical for its activity. The peptide was synthesized, cleaved, purified, analyzed, and an enzyme assay was
run. Michaelis Menton and Lineweaver-Burk plots were constructed to determine the Vmax, Km, and Ki for
each assay and determine the activity. It was determined that the assays yielded inconclusive data, and
therefore, it could not be determined whether competitive inhibition was occurring. Also the Kis for the
synthesized peptide and the native peptide were extremely different which also tells us that this is not
going to be a useful drug for diabetic patients.
Abstract 2: The LL-21 is the smallest active sequence for the antimicrobial LL-37 peptide. Were LL-37 is a
natural human immune defense and uses a different mechanism (drugs like penicillin which only attack
bacteria during reproduction state) of entry into the bacterial cell wall. The research consisted of
determining the activity of LL-21 against different bacterial strains. The methods to determine its activity
were to synthesize, cleave, purify, and then send peptide to our U of M sponsor to analyze. The peptide
was found to be active in the 0.4 to 100 μg/ml range. Further studies would use isotopically labeled
groups on the peptide and be studied thoroughly by the NMR to find the mechanism of action.
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Abstract 1: α-Amylase is an important enzyme in the body responsible for hydrolyzing
many polysaccharides such as dietary starch. Inhibition of this enzyme could be
extremely beneficial in diabetic patients because it could lower the glucose levels in the
blood. Our objective is to synthesize a small analog of a natural α-amylase inhibitor,
Tendamistat. This molecule has 15-22 residue segment that are critical for its activity.
The peptide was synthesized, cleaved, purified, analyzed, and an enzyme assay was run.
Michaelis Menton and Lineweaver-Burk plots were constructed to determine the Vmax,
Km, and Ki for each assay and determine the activity. It was determined that the assays
yielded inconclusive data, and therefore, it could not be determined whether competitive
inhibition was occurring. Also the Kis for the synthesized peptide and the native peptide
were extremely different which also tells us that this is not going to be a useful drug for
diabetic patients.
Abstract 2: The LL-21 is the smallest active sequence for the antimicrobial LL-37
peptide. Were LL-37 is a natural human immune defense and uses a different mechanism
(drugs like penicillin which only attack bacteria during reproduction state) of entry into
the bacterial cell wall. The research consisted of determining the activity of LL-21
against different bacterial strains. The methods to determine its activity were to
synthesize, cleave, purify, and then send peptide to our U of M sponsor to analyze. The
peptide was found to be active in the 0.4 to 100 µg/ml range. Further studies would use
isotopically labeled groups on the peptide and be studied thoroughly by the NMR to find
the mechanism of action.
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Introduction

I worked on two projects this year for my undergraduate research. One of them
focused on α-amylase inhibitors and their activities which could be beneficial for
diabetics. The other was to synthesize the smallest and most active sequence of the
antimicrobial peptide LL-37 and understand the molecular basis of its membrane
disruption.
Introduction to α-amylase and Tendamistat research
Alpha-amylase enzyme catalyzes the endohydrolsis of α (1->4) glycosidic
linkages in common polysaccharides (starches) from the diet, to regulate blood sugar
levels (Figure 1). During the disease state of diabetes mellitus, this enzyme can be
detrimental, due to the biochemical defect causing blood glucose levels to be elevated.
Inhibition of the enzyme’s activity would lower glucose absorption by the small intestine
and would control the elevation of glucose levels.
undigested starch to make it to the colon.
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This would then allow more

Figure 1: The polymeric structure of glucose in starch tends to be formless (1).
The goal of the project was to develop a small peptide drug based on the natural analog,
Tendamistat. Tendamistat is a tight-binding 74 amino acid long protein that specifically
inhibits mammalian α-amylase (Figure 2).

To better understand the structural,

conformational, and molecular-level interactions, it might be better to study smaller
analogs of Tendamistat.

Figure 2: is the 74 amino acid long Tendamistat, The only secondary structure found in
the protein are six beta sheets shown here in blue. The protein also contains two disulfide
bridges; Cys11-Cys27 and Cys45-Cys73 which are shown in pink (2).
This protein inhibitor was isolated from Streptomyces (expressed on surface of the
filamentous bacteriophage M13), of which only 8 amino acids are essential for the
inhibitor’s direct interaction with the enzyme binding site, which are Tyr-Gln-Ser-TrpArg-Tyr-Ser-Gln (Figure 3). This was discovered by x-ray crystallography and nuclear
magnetic resonance (3,4). This work suggests that a small portion of this peptide is
responsible for binding to the novel site.

Tendamistat is a pseudo-irreversible inhibitor of mammalian α-amylase with a Ki
value of 9 X 10-12 M (5). Topographical changes are induced in the enzyme, but not in
the inhibitor, upon binding (5).

There is a 1:1 stoichometric complex between

Tendamistat and the enzyme which blocks the access of glycogen or starch, therefore
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stopping the enzyme’s functionality. Further computational studies have modeled the αamylase-Tendamistat complex and discovered that approximately 30% of the inhibitor’s
water accessible surface area is in contact with the enzyme (5). The disulfide bonds
formed by Cys11 and Cys73 in Tendamistat are crucial for the inhibitor’s activity, since
they give rise to the smaller loop. The inhibitor has 15 important amino acids responsible
for direct interaction with the enzyme binding site via hydrogen/ hydrophobic bonding
and electrostatic forces (segments shown below) (6).
Segment 1: Tyr15 Trp18 Arg19 Tyr20
Segment 2: Leu44 Tyr 46
Segment 3: Gln52 Ile53 Thr54 Thr55
Segment 4: Asp58 Gly59 Tyr60 Ile61 Gly62
Segment 1 is responsible for binding at the catalytic site and blocking the natural
substrates while the other segments contribute to the recognization of specific αamylases. Segments 1 and 3 are responsible for β-sheet structure, while segment 2 is
involved with a partial β-sheet, stabilized by disulfide bonds. Segment 4 helps stabilize
the β-turn of the crucial triplet by being adjacent to segment 1 (6).
The critical residues used in our analogs from Tendamistat are from 15-22. This
is an important sequence because of Tyr15 which loops around to hydrogen bond with Gln
22

and is important for mammalian activity. Specifically the Trp19, Arg20, and Tyr21 form

a β-turn in Temdamistat such that the large positive side chain by the N-terminus is able
to loop out and interact with the enzyme (negative charge on amylase interacts with the
positive charge on Arg20) (5).
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There are several reasons why developing a smaller analog is beneficial. First, a
large molecule has detrimental side effects and may trigger an immune response, which
could cause the patient harm. Next, digestive enzymes could attack the natural protein
because it lacks novel amino acids and the drug would never reach its target. Even
though Tendamistat is resistant to hydrolases and denatures only at temperatures as high
as 90°C (5), additional unnatural amino acids incorporated into the sequence could give it
additional protection. Also smaller peptides are less costly for large scale production.
Lastly smaller sequence are easily studied structurally and more readily modeled. Since
Tendamistat is a well studied protein it is advantageous in determining a general small
analog which will be able to mimic the larger one.

This could ultimately be a

pharmaceutical drug that would be beneficial to patients with diabetes mellitus whether
young or old. Also, this drug might have another type of mechanism from typical
polysaccharides inhibitors.
Small

analogs

that

mimic

a

macromolecule

in

conformational

and

physicochemical characteristics may also mirror its binding properties. Other studies
have been performed to minimize the Tendamistat sequence. The peptide c(D-Pro-PheSer-Trp-Arg-Tyr) gave a Ki value of 14μM,while if Ser was replaced by Ala it gives the
value 32 μM. Linear tri-to hexapeptides bound with weaker affinity; the best, Ac-TrpArg-Tyr-OMe acts as a competitive inhibitor with an inhibition constant of 100 μM (5).
The significance of this study is that about 8 million Americans suffer each day
from diabetes mellitus. Even though there are other treatments such as insulin therapy,
diet, hyperglycemic agents, and other drugs, other agents would be useful. The related
complications for diabetes mellitus have been a result of hyperglycemia, which affects
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vascular permeability, blood flow, as well as nerve transmission (5). Consequently, by
reducing hyperglycemia, a drug could slow down or reverse processes in retinal, kidney,
nerve, and vascular tissue. This work might lead to a peptidomimetic drug or foundation
for treatment. These studies could further develop our grasp on molecular interactions at
the α-amylase active site, which may lead to other research and development of other
ligands.

Figure 3: Restrained energy refinement with two different algorithms and force fields of
the structure of the alpha-amylase inhibitor Tendamistat determined by NMR. The figure
to the right is the Tendamistat in aqueous solution by nuclear magnetic resonance and
distance geometry (4).
Tendamistat must be broken down into a smaller sequence because
otherwise it will be destroyed by the immune system network due to its massive size.
This is why it is broken down for potential drugs into smaller analogues that contain the
key amino acids. The most effective analogue developed in our lab thus far is NFH-1 (KI
= 6.7 x 10-5 M), which is (Ac)-Tyr-Gln-Ser-Trp-Arg-Tyr-Ser-Gln-(NH2). Note the serine
residues present on either side of the key triplet; this gives rise to hydrogen bonding
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capability intramolecularly and intermolecularly, but the hydroxyl group can effect side
reactions. The side reactions (interaction with other agents and no loop formation into
preferred pattern) could cause the inhibitory activity to be altered and lead to ineffective
pharmaceutical activity (5). The same is true for the hydroxyl group on the Tyr residue
(Figure 4).
This parent analog (Tendamistat 15-22) was slightly altered and synthesized as pNH2Phe-Gln-Ser-Trp-Arg-Tyr-Ser-Gln (figure 3).

This sequence should also attain

additional hydrolytic stability, leading to enhanced bioavailability, and alternative folding
patterns. The first residue has an NH2 on the para position of the phenyl ring instead of a
hydroxyl group, as would be found on the natural tyrosine. The amine group was chosen
because it has similar characteristics as the OH on the Tyr. Observation of the activity of
the amine group at this position and how it compared to the OH group was accomplished
by enzyme assays. It was suspected that a similar H-bonding pattern would allow the
required β turn loop, which is crucial to its activity, but the amine may be less reactive
with other species. (5)

aromatic
Tyrosine Tyr Y
polar
hydrophobic

Figure 4: The tyrosine residue with its Rasmol image, 3 and 1 letter code, properties and
structure (3).
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Our sequence as shown previously is p-NH2Phe-Tyr-Gln-Ser-Trp-Arg-Tyr-SerGln, where we added the NH2 to the para position on Phe instead of the OH in Tyr. The
resulting peptide was tested for activity using spectrophotmetric analysis and
Lineweaver-Burk plots were used for KI calculation and comparison.
Introduction to LL-21 research
The other project is based on the LL-37 sequence from the human defense system.
LL-37 is naturally expressed in neutrophils and epithelial tissues in humans. This is the
first line of defense against bacterial infections, which is accomplished by destroying
bacterial membranes through either a detergent-like mechanism (Figure 5) or pore
formation. The carpet or detergent mechanism would show the LL-37 attacking the
bacterial cell wall, deteriorating it by surrounding its lipids in a micelle, and sending the
pieces off to macrophages to be released from the body. This means that the peptide
molecules surround and pull apart the membrane lipids, destroying the membrane
structure of bacteria. The other mechanism shown is the barrel-stave, which disrupts the
cell was by placing multiple LL-37 molecules in a circular form throughout forming
pores through which the cell contents can escape. This works because the hydrophobic
part allows for penetration of the lipid membrane, disrupting membrane structure by
creating many holes, resulting in cell death. These transmembrane pores upset the
electrochemical gradient which leads to osmosis and cell rupture. These mechanisms are
suggested to be due to the amphipathic sequence of LL 37 (polar/nonpolar mix). The
positive charge of arginine and lysine residues attract specifically to bacterial membranes,
because of the bacteria’s negatively charged phosphatidyl esters (P.E.) (8).
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The

mammalian cell membranes contain more positively charged phospholipids so do not
attract the peptide. This mechanism of attack may be helpful in drug discovery since it
focuses on bacterial cells when not replicating and is unlike any other method thus far on
the drug market. Also the bacteria should not acquire resistance to this mechanism.

Figure 5: The detergent (carpet) and barrel mechanism
The amphipathic nature and natural activity of LL-37 make this an excellent candidate
for drug studies. The positive portion attracts it to bacterial membranes, and the
hydrophobic portion can then penetrate the lipid membrane. The preliminary results
suggest that its salt-resistant antimicrobial activity, significant resistance to proteolytic
degradation, aggregation state, structural stability, and predicted N-terminal structure
differ from the well-studied antimicrobial peptides of this class, such as Leptospira
interrogans, Borrelia, and Treponema pallidum (7). These differences affect features
critical to the proposed pore model shown in figure 5, and suggest a unique mechanism
for LL37. (2)
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The sequence of this synthetically prepared fragment of the human antimicrobial
peptide LL37 is RKSKEKIGKEFKRIVQRIKDF (Figure 6). The LL-21 sequence was
chosen by cutting each amino acid from the N and C terminus and checking its activity.
This then allowed our collaborators to discover the most important sequence which was
the amino acids 1-21 on the N-terminus (8). LL37 is a member of the cathelicidin family
and has a potently antimicrobial C-terminal domain.

It has a distinct α-helical

conformation, especially if near negatively charged lipids. It also has been shown to help
in recruiting cellular immune response as a chemoattractant (9). These characteristics
indicate that the LL21 fragment is capable of antimicrobial activity. Developing a shorter
sequence than parent is economically and synthetically advantageous as discussed in the
first project.
Previously to obtain information on lipid specificity our collaborators at U of M
measured the attraction to different types of cell membrane model liposomes using
fluorimetry experiments. This suggested that the peptide was more attracted to the
negatively charged model over the neutral or positively charged forms.

RKSKEKIGKEFKRIVQRIKDF
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Figure 6: The LL-21 structure shown as a ball and stick model. The positively
charged Arg (R) and Lys (K) residues confer specificity for bacterial membranes.
This study might give way to other drugs based on amphipathic peptides and help
people who are immune deficient. Also, antimicrobial peptides may be of special interest
in the dental fields, as they are found in mucosal epithelial cells; their activity can help
against oral disease, such as P. gingivalus.(11) Furthermore, if used in combination with
other antibiotics, they may have a synergistic effect on the body. There is also a demand
for new antibiotic drugs that cannot progress to become resistant to infectious organisms.
These peptides inhibit the growth of both Gram-positive and Gram-negative bacteria (12)

Materials and Methods
Each amino acid in the sequence was weighed out at 0.4 mmoles along with 0.152
g

(0.4

mmoles)

of

O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-

phosphate (HBTU, a peptide coupling agent) in separate vials. These were then put into
the PS3 protein synthesizer in the sequence of the peptide from the C-terminal to Nterminal residue corresponding to the specified analog of Tendamistat or LL21
peptide.(Figure 7). A vial of acetic anhydride was placed two positions away from the Nterminus to acetylate the Tendamistat peptide for the purpose of keeping the N-terminus
from becoming charged. The reaction vessel contained 0.1648 g of Fmoc-Rink Amide
MBHA resin (9-fluoronylmethyloxycarbonyl Rink amide methylbenzyhydylamine resin)
and a small amount of DMF (N,N-dimethylformamide). This resin results in a
carboxamide at the C-terminus after cleavage. The solutions required for synthesizing
were 0.4 M DIEA (N,N-diisopropylethylamine/DMF (activator)), and 20% piperidine
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(deprotectant) in DMF. The synthesizer was used to attach the terminal amino acid to the
solid resin support, and, then it coupled each amino acid by forming amide bonds with
the aid of coupling agents, selective deprotectents, and solvent washes. The Tendamistat
peptide was programmed for single coupling, while the LL21 analog was double coupled
(2 vials of each amino acid at each position). This is because LL21 is a much longer and
more

difficult

sequence

than

the

Tendamistat octapeptide. Also, couplings 5-15 in a sequence tend to be difficult
as

the

longer

chain

starts

to

form

secondary

structures

during

the

synthesis. So double coupling assures completion of each step, resulting in fewer
impurities and higher yield.

Figure 7: The PS3 synthesizer.
After the synthesis was completed we performed cleavage and work up of the
newly formed peptide. The reaction vessel from the synthesizer was rinsed with
methanol, ethanol, and methylene chloride, respectively and then the peptide resin was
dried for half an hour under vacuum. Next, we prepared the cleavage cocktail, which had
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0.5 ml anisole and 0.5 ml of water in a separate beaker. Since the sequence contained a
Trp residue we added 0.5 ml thioanisole. Thioanisole is just another scavenger (phenylSCH3) that traps carbocations generated in the cleavage process (since it's an
electrophilic aromatic substitution substrate). The Trp side chain indole ring is notorious
for having things add back, giving unwanted adducts, so the extra scavenger helps
alleviate this. Then we added one crystal of phenol and 10 ml of trifluoroacetic acid to
the cocktail. The anisole, thioanisole, and phenol were added because they act as
scavengers for any reactive species generated during the cleavage. The cocktail was
stirred for about 5-10 minutes on ice before adding this to the resin. The cocktail and
resin was covered with parafilm and removed from the ice bath next, this was stirred at
room temperature for 1-2 hours and the solution turned yellow.
A side arm flask and filter funnel was set up for pouring, and the cleavage mixture
was poured through a filter funnel and collected in a side arm flask. The beaker from
which the mixture was poured was washed 2-3 times with miniscule amounts of TFA to
ensure quantitative transfer Then 50 mL of cold diethyl ether was added to the TFA
solution, slowly while stirring, which caused the peptide to precipitate. Since this is an
exothermic reaction it was carried out in an ice bath to maintain temperature and prevent
side reactions. Another side arm flask was set up with a fine disc Buchner funnel, and
the precipitate in ether was poured in. Then 10 mL of ether was added to the funnel and
the precipitate was stirred with a stainless steel spatula. This was done a couple of times
to make sure all the thioanisole was removed. The flask was changed and the peptide
was dried under water aspirator. Once this was completed, it was transferred to a small
lyophilization flask and 70% acetonitrile/H2O was added. An equal amount of distilled
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water was added to the mixture and then it was placed in a dry ice/acetone bath to freeze
while rotating.

This increased the surface area for lyophilization which took place

overnight.
The next step was to perform High Performance Liquid Chromatography (HPLC),
which purifies the peptide by removing any leftover scavengers or other impurities that
may be present. The peptide was first completely dissolved in a small amount of DMF
and loaded into the HPLC machine with a syringe. Gradient program two was run, which
is a linear gradient of 10% to 50% acetonitrile (solvent B)/water (solvent A) over two
hours. The best peaks were observed and were collected in tubes. These were then
lyophilized and an analytical HPLC was used to determine the purity of the peptide. This
was the point at which our contribution to the LL-21 peptide research was complete.
Collaborators at the University of Michigan continued the project through extensive
studies of the LL-21 peptide active. The LL-21 was tested against a variety of gram
positive and gram negative bacteria. Some analogs will later be isotopically labeled
peptides for solid state NMR studies, providing information on the membrane orientation
and mechanism of action.
The last step for the Tendamistat analog was to perform three enzyme assays to
determine the activity of α-amylase in the absence and presence of our synthesized
inhibitor. Each assay was done in the same way but with varying concentrations of
inhibitor (0.1, 0.2, and 0.3 mM) for each trial. The total volume in each tube was 1000
μL, with different volumes of buffer and substrate. The volumes/concentrations of the
enzyme and inhibitor/DMSO (DMSO only for the control or the uninhibited tubes) were
constant. The substrate (p-nitropenyl- α-D-maltoside ) was bought already packaged in a
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50 mg vial (bought from Calbiochem, Inc). It was prepared by dissolving it in 2300 μL
of Hepes buffer at pH 7. The enzyme preparation of α-amylase (isozyme I, bought from
Sigma Corp.) was done by dissolving 46 μL of porcine pancreatic α-amylase in 454 μL of
Hepes buffer. The inhibitor concentrations of 0.1, 0.2, and 0.3 mM were prepared by
adding 1400 μL of DMSO to 1.01, 2.09, and 3.01 mg of synthesized peptide respectively.
There were 7 tubes prepared for the inhibitor and 7 tubes for the uninhibited run (each
with a varying amount of substrate) giving a total of 14 tubes. Table one shows the
volumes and preparation of each tube.

Table 1: The preparation of each set of tubes for the inhibited and uninhibited runs. The
DMSO volume for one set of tubes contains the inhibitor and the other set does not.
DMSO
Enzyme
Tube
[S] (mM)
Substrate
Buffer
Volume
Volume
Volume
Volume
(μL)
(μL)
(μL)
(μL)
#1
1.0
20
783.9
29.4
166.7
#2
3.0
60
743.9
29.4
166.7
#3
5.0
100
703.9
29.4
166.7
#4
8.0
160
643.9
29.4
166.7
#5
10.0
200
603.9
29.4
166.7
#6
13.0
260
543.9
29.4
166.7
#7
16.0
320
483.9
29.4
166.7
By varying the volume of the substrate and buffer, the concentration of the substrate
added each time was different even though the total volume remained the same. The
order of adding the substrate, enzyme, buffer and DMSO was crucial for reading
absorbance’s during the spectroscopy study because if not put in order the enzyme might
denature. The enzyme was added first, followed by the buffer and then the DMSO. The
tubes were incubated for 30 minutes without the substrate, at 30˚C After incubation, the
tube was taken out to be analyzed by UV/Vis spectroscopy. The substrate was added to
a tube, which was then vortexed to ensure complete mixture before placing it in the cuvet
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for reading. The UV/VIS spectrophotometer was set at 405 nm, because this is the
wavelength at which the product (p-nitrophenolate) has maximum absorbance. The
instrument was set to record the change in absorption/concentration of the product of the
reaction between the enzyme and substrate for 2 minutes with 10 second intervals
between readings. The rates of the increasing absorption/concentration for each tube
were recorded and then analyzed using Excel. Beer’s Law was used to determine the
concentration from the absorbance. Michaelis-Menton and Lineweaver-Burk graphs were
made. These plots allowed determination of the Vmax, Km, and Ki of each of the three
assays and the average Ki for all the assays.

Results
Αlpha-amylase results
The results for the α-amylase inhibitor runs are shown first, and then the LL-21
results are given. Both Lineweaver-Burk plots and Michaelis Menten plots are provided
for each run in Figure 8 through Figure 13. This illustrates the activity of the enzyme as
the concentration of the inhibitor increases by 0.1mM in each reaction. Figure 8 shows
the Lineweaver Burk plot of 0.1 mM of the inhibitor, where the inhibited best fit line is
steeper as expected. In Figure 9 there is a Michaelis Menton Plot of the inhibitor at 0.1
mM it shows the inhibited run is slightly lower in activity than the uninhibited run and
only the fifth point could cause concern (but is probably due to experimental error).
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Figure 8: Lineweaver-Burk plot of 0.1 mM of the inhibitor.
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Figure 9: Michaelis Menton plot of the inhibitor at 0.1 mM
Figure 10 and 11 show the Lineweaver-Burk plot and the Michaelis Menton plot
respectively for the 0.2 mM run. Some of the points for inhibited run show better activity
than uninhibited, but overall, the data show inhibition by the peptide.
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Figure 10: Lineweaver-Burk plot of the inhibitor at 0.2 mM.
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Figure 11: Michaelis Menton plot of the inhibitor at 0.2 m
Figure 12 and 13 are similar to 8 and 9, since the data is consistent with the uninhibited
enzyme being of lower activity than the inhibited. Points 4 and 7 are questionable but on
the whole, the plots show inhibition.
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Figure 12: Lineweaver-Burk plot of the inhibitor at 0.3 mM.
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Figure 13: Michaelis Menton plot of the inhibitor at 0.3 mM
Tables 2-4 give the results of the three assays run. The data given is the rate of
control runs and the rate of inhibited runs (as measured by an increase in absorbance,
indicating increased formation of product) for the amount of substrate added to each vial.
Table 2 provides the results for the enzyme with 1 mg of inhibitor and most of the data
shows that the control rates are greater than the inhibited ones. Table 3 has the rates of
the enzyme at 2 mg of inhibitor and this assay has contradicting data since it shows both
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increase and decrease of inhibited in comparison to control. Table 4 is similar to Table 2
with most of its data being consistent with what we would expect.

Table 2: The rates of the enzyme at 1 mg (0.1 mM) of inhibitor
Tube

[S] (mM)

#1
#2
#3
#4
#5
#6
#7

1.0
3.0
5.0
8.0
10.0
13.0
16.0

Rate of
(dA/min)
0.0025
0.0065
0.0096
0.0156
0.0135
0.0158
0.0258

control Rate of inhibited
(dA/min)
0.0021
0.0048
0.0086
0.0096
0.0142
0.0135
0.0181

Table 3: The rates of the enzyme at 2 mg (0.2mM) of inhibitor
Tube

[S] (mM)

#1
#2
#3
#4
#5
#6
#7

1.0
3.0
5.0
8.0
10.0
13.0
16.0

Rate of
(dA/min)
0.0015
0.0052
0.0059
0.0107
0.0123
0.0091
0.0178

control Rate of inhibited
(dA/min)
0.0012
0.0011
0.0027
0.0117
0.0086
0.0201
0.0117

Table 4: The rates of the enzyme at 3 mg (0.3 mM) of inhibitor were as follows:
Tube

[S] (mM)

#1
#2
#3
#4
#5
#6
#7

1.0
3.0
5.0
8.0
10.0
13.0
16.0

Rate of
(dA/min)
0.0024
0.0065
0.0112
0.0104
0.0151
0.0182
0.0206
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control Rate of inhibited
(dA/min)
0.0017
0.0034
0.0047
0.0118
0.0077
0.0171
0.0218

Sample Calculations.
Vmax, Km, and Ki were determined from the equation of the line given on the LineweaverBurk plot. We used Vmax and Km for uninhibited/control runs and prime values (Vmax’ and
Km’) for inhibited.
0.1mM Inhibitor
Uninhibited
Vmax = 1/y-int = 1/3.55 X 1005 = 2.853 X 10-06 M/min
Inhibited
V’max = 1/ 2.527 X 1005 = 3.960 X 10-06 M/min
Uninhibited
Km= slope * V max = (3.941 X 10-06 )(2.853 X 10-06 ) = 11.24 mM
Inhibited
K’m = (3.316 X 10-06 )(3.96 X 10-06 ) = 13.13 mM

Ki : inhibited m = uninhibited slope (1 + ( [I]/Ki)
Ki =0.53 mM = 531 µM

This was then done for the two other assays and the results for those follow.

0.2 mM inhibitor
Vmax =9.132 X 10-06 M/min
V’max = 5.848 X 10-06 M/min
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Km = 6.975 mM
K’m = 32 mM
Ki = 0.579 mM= 579µM

0.3 mM inhibitor
Vmax = 2.120 X 10-06 M/min
V’max = 3.941 X 10-06 M/min
Km = 10.55 mM
Km’ = 13.56 mM
Ki = 0.647 mM= 647µM
Average Ki:= ((Ki1 +Ki2 + Ki3)/3) = 0.595 mM = 595µM
Another way to determine Ki is to plot [I] vs the slope of the Lineweaver-Burk plot (Fig
14). The negative of the x-intercept is the Ki. This method gave a Ki of 758 μM which is
very close to the averaging method of each individual run.
The parent peptide NFH 1 (Tendamistat 15-22) gives an average Ki of 375 μM (for
Tyrosine1).
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Ki Determination
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Figure 14: KI determination plot.
LL-21 Results
In the other experiment (activity determination for LL21) the ability of the peptide to
inhibit the bacteria is shown in Table 5, where it gives the minimum inhibition
concentration (MIC). Figure 15, the concentration vs. activity plot for S. enterica and S.
aureus are a representation of LL-21 activity.

Table 5: Different bactria strains studied to show the minimum inhibitory concentration
of LL21. Gram stains (+) or (-) indicated.
Bacterial Strain

LL21 / MIC (μg/ml)

Porphyromonas gingivalis W83 (-)

12.5

25

Staphylococcus aureus (+)

50

Salmonella enterica (-)

50

Pseudomonas aeruginosa (-)

100

S. Gordonia (+)

6.25

Enterococcus feacalis FA2-2 (+)

12.5

Enterococcus feacalis OG1X (+)

50

Escherichia coli (-)

0.4

LL21 MIC: S. enterica & S. aureus
120
100
80
S. enterica
S. aureus

60
40
20
0
100

25

6.25 1.56 0.39

0.1 0.02 0.01

0

0

0

LL21 Concentration (microgram/ml)

Figure 15: The concentration vs. activity plot for S. enterica and S. aureus as a
representation of LL-21 activity.
Discussion
Each assay varied in its results, so the first assay will be discussed first. The
Michaelis Menten plot is good for observing the correlation between the inhibited and
control curves. This plot allows an estimation of the Vmax and Km for each particular
assay. Since the parent peptide, Tendamistat, is a competitive inhibitor of α-amylase,
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then our peptide should also shows signs of competitive inhibition. The Vmax and Km for
the uninhibited and inhibited reactions were fairly similar (for 0.1 mM Vmax=2.85 X 10-06
M/min for uninhibited and 3.96 X 10-06 M/min for inhibited while Km for uninhibited is
11.24 mM and 13.13 mM for inhibited.). There was one noted error on the fifth data point
by the uninhibited being higher than the inhibited for both runs which could be due to an
error in preparation (e.g. substrate or enzyme not mixed well before addition to each
tube). This could not be repeated due limited peptide, time to re-synthesize peptide, and
expense of substrate. Since there is less than a two fold difference in the parameter
values, it is not considered a drastic change (only when the magnitude is 10 to 100 fold
different is it considered significant). Since the Lineweaver-Burk plot takes the double
reciprocal of the data and a best fit line is drawn, it tends to average the points so that one
bad point does not often grossly influence the plot (Figure 8).

This linear plot is

considered a better representation of the data obtained. The fact that the lines cross near
the origin makes it difficult to determine if the inhibition is competitive or
noncompetitive, which is likely due to insensitivity in our assay. This run appears to
show competitive inhibition because the lines intersect near the y-axis, but not close
enough to be certain. The calculations to determine the Vmax, Km and Ki were performed
using the equation of the line as shown previously. The Vmax for the uninhibited and
inhibited runs were extremely close. The Km for the two trials was fairly close. The Km
for the inhibited run was slightly lower than that of the uninhibited one, which is not
expected for competitive inhibition; however, the values are not significantly different
which simply indicates that inhibition is weak. In conclusion the data for this assay did
correlate with the hypothesis even though one point was misleading, which could be due

27

to an error in the experiment. The dA/min is decreasing for each inhibitor tube which
shows that there is inhibition taking place in the tubes. This run could be repeated in the
future to ensure accurate interpretation of results.
The second assay exhibited about the same Vmax values even though there were a
couple places where the curves crossed each other in the Michaelis-Menten plot (Table 3
and Figure 11). An error could have occurred in not using the Pipetman pipettor
accurately. Upon analysis of the Lineweaver-Burk plot, the reaction exhibited inhibition,
this time with lines crossing closer to the x-axis, an indication of non-competitive
inhibition. The calculated Vmax values again are very similar values, where there is about
a 36% difference. This is only a less than 2- fold difference in magnitude, however, and
not considered significant. The Km did show an increase for the inhibited run (32 mM
versus about 7 mM , almost a 5-fold change), another indication of non-competitive
inhibition, although weak.
The final assay was similar to the first assay and the Michaelis Menten plots were
fairly similar with only two odd points. The values for Vmax and Km respectively for the
inhibited were 3.94 X 10-06 M/min and 13.56 mM while the uninhibited values were 2.12
X 10-06 M/min and 10.55 mM. The Lineweaver-Burk plot exhibited the lines intersecting
slightly to the left of the y-axis, but above the x-axis (type of inhibition inconclusive).
The calculated Vmax values were fairly close which can indicate competitive inhibition
(uninhibited was actually14% lower than inhibited), and the Km was slightly increased for
the inhibited run relative to the uninhibited run. Still, the values were very similar
between assays, indicating weak inhibition.
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In conclusion, inhibition took place but the data was not conclusive as to which
type. Also comparing Ki values for the parent peptide (NFH-1) and our synthesized
peptide, the value for our analog is higher (ave. 595 μM versus 375 μM for NFH-1, lower
values indicating better inhibition), indicating weaker interaction with the enzyme. This
showed that this is not in the desired nanomolar range for drug development and it has
poor activity. Since –NH2 and -OH are very similar in size, electronic character, and the
ability to act as both H-bond donors and acceptor, differences in activity between the
analogs is surprising. Still, the difference is less than 2-fold so not considered significant.
This sequence should either be assayed again to confirm the data or it could be modified
slightly to give better activity results. These results were somewhat inconsistent and it
was hard to determine what was occurring except that inhibition was taking place for the
most part. In future trials it might be good to conduct these assays sequentially right after
each other to ensure that the conditions are the same for each trial (pressure, temperature,
concentrations, etc). An alternate assay may also be developed.
The second experiment that I worked on was with the LL-21 peptide which
showed promising activity. The newly synthesized peptide required only slightly higher
concentrations compared to the parent LL37 to inhibit bacterial growth. Given its shorter
sequence, this is impressive. The best activity shown was against E. coli since its MIC
was 0.4 μg/mL, and any concentration below 10 μg/mL is useful. In the future we will
examine the three-dimensional structure of our analog and orientation with respect to the
membrane with NMR (with isotopic labels present for NMR studies) to give more
information on the exact mechanism of action. This is a good potential mechanism to
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treat infections with excellent societal implications since it may lead to the development
of an antibiotic to which the bacteria cannot develop resistance.
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